Date: 2012-02-29
Type of information:
phase: 1
Announcement: initiation of the dosing
Company: Proximagen (UK)
Product: PRX167700
Action
mechanism: Proximagen’s PRX167700 is an oral drug candidate that is expected to work by regulating the movement of immune cells from the blood into sites of inflammation, thereby modulating the underlying inflammatory process and relieving the symptoms of inflammation. This mode of action provides the potential for a disease modifying effect, whereby modulating the movement of the damaging immune cells to the sites of inflammation also stops further damage caused by the disease.
Disease: rheumatoid arthritis
psoriasis
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Dermatological diseases - Rheumatic diseases
Country:
Trial
details: This Phase I trial is a randomised, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of PRX167700 in healthy male subjects, and the effect of food on the pharmacokinetics of a single oral dose of the drug. The study will also investigate the relationship between the pharmacokinetic and pharmacodynamic effects of single and multiple ascending oral doses of PRX167700.
Latest
news: Proximagen has commenced dosing in a Phase I clinical trial of PRX167700, a Vascular Adhesion Protein-1 (VAP-1) antagonist, for the treatment of inflammation in rheumatoid arthritis (RA) and psoriasis. In addition to efficacy shown in models of RA, PRX167700 has demonstrated efficacy in models of multiple sclerosis and inflammatory pain. Regulating the movement of immune cells is also important in these two diseases, indicating that PRX167700 has potential utility in multiple disease areas of high unmet medical need. The first results are anticipated in H2 2012.
